Published in Clin J Am Soc Nephrol on July 11, 2013
The use of fibroblast growth factor 23 testing in patients with kidney disease. Clin J Am Soc Nephrol (2014) 0.86
Predictors and the Subsequent Risk of End-Stage Renal Disease - Usefulness of 30% Decline in Estimated GFR over 2 Years. PLoS One (2015) 0.80
Mortality and complications after hip fracture among elderly patients undergoing hemodialysis. BMC Nephrol (2015) 0.80
Circadian variation of mineral and bone parameters in end-stage renal disease. J Nephrol (2014) 0.78
The Impact of Normal Range of Serum Phosphorus on the Incidence of End-Stage Renal Disease by A Propensity Score Analysis. PLoS One (2016) 0.75
Variability in measures of mineral metabolism in children on hemodialysis: impact on clinical decision-making. Pediatr Nephrol (2017) 0.75
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2009) 12.66
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol (2004) 11.23
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis (1998) 7.79
Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA (2011) 5.86
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2008) 4.72
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol (2006) 3.36
High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant (2009) 3.08
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol (2007) 1.86
Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int (2012) 1.82
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78
CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J (2010) 1.73
Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules. Kidney Int (2005) 1.67
The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J (2011) 1.51
Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J (2011) 1.49
Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol (2012) 1.48
Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. Am J Kidney Dis (2008) 1.46
Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol (2012) 1.45
Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl (2009) 1.18
Fibroblast growth factor 23 in patients undergoing peritoneal dialysis. Clin J Am Soc Nephrol (2011) 1.13
FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant (2012) 1.07
Serum fibroblast growth factor-23 and risk of incident chronic kidney disease in older community-dwelling women. Clin J Am Soc Nephrol (2011) 1.05
Phosphate: a novel cardiovascular risk factor. Eur Heart J (2012) 0.90
Low molecular weight iron dextran increases fibroblast growth factor-23 concentration, together with parathyroid hormone decrease in hemodialyzed patients. Ther Apher Dial (2012) 0.88
Ultradian variation in serum phosphate concentration in patients on haemodialysis. Nephrol Dial Transplant (1995) 0.83
Evaluation of human fibroblast growth factor 23 (FGF-23) C-terminal and intact enzyme-linked immunosorbent-assays in end-stage renal disease patients. Clin Lab (2009) 0.82
Phosphate and FGF23 in early CKD: on how to tackle an invisible foe. Nephrol Dial Transplant (2011) 0.81
Variability in calcium, phosphorus, and parathyroid hormone in patients on hemodialysis. Hemodial Int (2009) 0.79
The circadian rhythms of blood ionized calcium in humans. Scand J Clin Lab Invest Suppl (1983) 0.78
Diurnal variation of serum calcium and phosphorus in postmenopausal women. Calcif Tissue Int (1986) 0.77
Psychiatrists' use of shared decision making in the treatment of schizophrenia: patient characteristics and decision topics. Psychiatr Serv (2009) 3.14
Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl (2007) 2.84
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
SuperSAGE evidence for CD14++CD16+ monocytes as a third monocyte subset. Blood (2011) 2.66
Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation (2005) 2.49
Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2011) 2.27
Erythropoietin regulates endothelial progenitor cells. Blood (2003) 2.18
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thromb Haemost (2004) 2.09
Stimulation of endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension (2005) 2.01
Monte Carlo simulations of a nozzle for the treatment of ocular tumours with high-energy proton beams. Phys Med Biol (2005) 2.00
A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial Transplant (2012) 1.94
Excess circulating angiopoietin-2 is a strong predictor of mortality in critically ill medical patients. Crit Care (2008) 1.94
CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol (2012) 1.92
Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. Kidney Int (2012) 1.92
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant (2006) 1.90
Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics (2010) 1.90
ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke (2006) 1.88
The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant (2009) 1.86
FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant (2010) 1.78
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol (2005) 1.74
CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J (2010) 1.73
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury. Crit Care (2010) 1.65
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63
Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med (2010) 1.59
CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl (2008) 1.57
Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. Am J Kidney Dis (2004) 1.55
Circulating angiopoietin-2 in essential hypertension: relation to atherosclerosis, vascular inflammation, and treatment with olmesartan/pravastatin. J Hypertens (2009) 1.54
Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med (2009) 1.53
The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J (2011) 1.51
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med (2006) 1.51
Preoperative statins improve recovery of renal function but not by an anti-inflammatory effect: observational study in 69 elderly patients undergoing cardiac surgery. Int Urol Nephrol (2011) 1.46
Monocyte heterogeneity in obesity and subclinical atherosclerosis. Eur Heart J (2009) 1.38
Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int (2003) 1.33
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 1.32
Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int (2004) 1.29
Uremia causes endothelial progenitor cell deficiency. Kidney Int (2004) 1.27
Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol (2007) 1.24
Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis (2005) 1.24
Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond) (2004) 1.23
Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant (2010) 1.23
Pulmonary hypertension in CKD. Am J Kidney Dis (2012) 1.19
Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl (2009) 1.18
Renal resistive index and cardiovascular and renal outcomes in essential hypertension. Hypertension (2012) 1.16
Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A (2003) 1.16
Monocyte heterogeneity in human cardiovascular disease. Immunobiology (2012) 1.15
Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications (2005) 1.12
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant (2010) 1.08
Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens (2009) 1.07
FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrol Dial Transplant (2012) 1.07
Diagnostic value of N-terminal pro-B-type natriuretic peptide (NT-proBNP) for left ventricular dysfunction in patients with chronic kidney disease stage 5 on haemodialysis. Nephrol Dial Transplant (2007) 1.05
Masking misfit in confirmatory factor analysis by increasing unique variances: a cautionary note on the usefulness of cutoff values of fit indices. Psychol Methods (2011) 1.04
Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant (2008) 1.03
Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol (2006) 1.03
Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis (2003) 1.02
Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nat Rev Nephrol (2012) 1.02
Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nat Rev Nephrol (2011) 1.01
Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 1.01
B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: the Mild-to-Moderate Kidney Disease Study. Clin Chem (2007) 1.00
Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation (2004) 0.99
Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant (2014) 0.98
Endothelial progenitor cells and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. PLoS One (2010) 0.98
Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care (2012) 0.95
Prometheus--a new extracorporeal system for the treatment of liver failure. J Hepatol (2003) 0.95
Illegal performance enhancing drugs and doping in sport: a picture-based brief implicit association test for measuring athletes' attitudes. Subst Abuse Treat Prev Policy (2014) 0.94
Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant (2013) 0.93
Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial. Atherosclerosis (2009) 0.92
Ren sanus in corpore sano: the myth of the inexorable decline of renal function with senescence. Nephrol Dial Transplant (2005) 0.92
Circulating monocyte subpopulations with high expression of angiotensin-converting enzyme predict mortality in patients with end-stage renal disease. Nephrol Dial Transplant (2010) 0.92
Circulating levels of osteopontin are closely related to glomerular filtration rate and cardiovascular risk markers in patients with chronic kidney disease. Eur J Clin Invest (2010) 0.92
High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int (2011) 0.91
Kidney graft function determines endothelial progenitor cell number in renal transplant recipients. Transplantation (2005) 0.91
Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease. Nephrol Dial Transplant (2006) 0.91
Risk factors for nonocclusive mesenteric ischemia after elective cardiac surgery. J Thorac Cardiovasc Surg (2012) 0.91
Combined top-down and bottom-up mass spectrometric approach to characterization of biomarkers for renal disease. Anal Chem (2005) 0.90
SuperTAG methylation-specific digital karyotyping reveals uremia-induced epigenetic dysregulation of atherosclerosis-related genes. Circ Cardiovasc Genet (2012) 0.90